Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit
21 oct. 2021 08h00 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
29 sept. 2021 07h00 HE
|
Solid Biosciences Inc.
- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post...
Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
23 sept. 2021 06h00 HE
|
Solid Biosciences Inc.
- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital...
Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
20 sept. 2021 16h05 HE
|
Solid Biosciences Inc.
- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021...
Solid Biosciences to Participate at Upcoming Investor Conferences
20 sept. 2021 16h01 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021
24 août 2021 08h00 HE
|
Solid Biosciences Inc.
- Chief Operating Officer to discuss company’s advanced AAV gene therapy manufacturing capabilities and best practices for orphan drug development - CAMBRIDGE, Mass., Aug. 24, 2021 (GLOBE NEWSWIRE)...
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance
19 août 2021 08h05 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance
19 août 2021 08h00 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results
16 août 2021 16h11 HE
|
Solid Biosciences Inc.
- Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 - - Development activities continue for pipeline initiatives SGT-003 and Ultragenyx...
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development
02 juil. 2021 08h00 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...